Roche’s alzheimer’s drug clears plaques in 28 weeks, faces 2028 test to slow memory loss

Roche's experimental Alzheimer's drug, trontinemab, has shown promising results by clearing harmful protein deposits from the brains of nine out of ten patients within 28 weeks. However, the drug faces a critical test in 2028 to determine if it can slow memory loss. This development offers hope for Alzheimer's treatment, but further research is needed. The drug's efficacy in slowing cognitive decline will be evaluated in future trials.

Read More